If 1 individual or entity accounted for, on average, just 15% of the volume over the last 3 weeks, they would own 5% and would be required to file a form 13 within 10 days. It's very unlikely that tons of small players just simultaneously decided to buy. I think we have to see some new 5% holders by the end of next week. Could be interesting...
The stock is now trading nicely. No more worries about liquidity! It seems like our streak of luck is due to end here soon. I can't imagine that the stock gains $0.30-0.50 this week for a 4th week in a row, but we'll see. Still holding 100% of original position.
yeah pretty good news flow here. Maybe next we will see news on the label expansion.
Nice. You're exactly right, these guys know the company better than anyone and it speaks volumes that they are pouring their own cash into it.
I can't imagine that our good fortune will continue for a 4th week in a row, but we'll see. These form 4s definitely won't hurt. With the Prosl patent news out, I'm not really sure what is next. Maybe partnering in Asia or the Middle East? Canada?
There is a chunk of shares for sale at $11.25. If we eat through those, this will close at $12, but my guess is there is not enough demand to eat up those shares and that will keep the lid on this...for now.
I have not sold 1 single share of CRMD, but given the run we've had, I am taking on more risk and I believe ADMD could be the next CRMD. The company is expecting FDA approval by the end of this month. They have a plan in place to recapitalize and launch the product. Tons of insider ownership and insiders continue to support the company. Trading around $0.06-0.07 right now. I fully expect it will be $0.70 in February IF they get their approval as expected.
That is what I'm betting on. They don't need it to be successful, but if they can knock out TP, this could jump to $15+ in the blink of an eye.
Man, you must be regretting your short position already. Trading $9+ in pre-market and Martin is saying on Twitter he's going to be making some open market purchases soon.
I used google translate to craft this message such that our friends at TauroPharm could read it:
Cormedix kommt für Sie TauroPharm. Ihre Jahre hocken auf unser geistiges Eigentum, sind vorbei.
I downloaded the bulletin but I'm searching for it and can't find it. The document is 1100 pages long. I've searched for Prosl, ND Partners, taurolidine, heparin, etc etc so not sure why I'm not seeing it. Anyone?
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced that it has entered into securities purchase agreements with investors pursuant to which it has agreed to sell 200,000 shares of Series C-3 Non-Voting Convertible preferred stock and a warrant to purchase up to 1,000,000 shares of common stock for aggregate gross proceeds of $2,000,000. This is the second tranche of funds contemplated and priced in the company's October 2013 Series C preferred stock financing to bolster the Company's cash position which management now projects to be sufficient to fund operations through the achievement of a break even sales run rate. The net proceeds of the financing will be used for general corporate purposes, including the development and commercialization of Neutrolin®, and working capital and capital expenditures. No underwriter or placement agent was used in this transaction.
figure this deserves it's own post. The parallels between CRMD and GTHP are kind of striking. Both got CE Mark and are striving towards FDA approval. Both are relatively broke. CRMD hopefully will follow in GTHPs footsteps and ink a lot of deals in France, Malaysia, etc. GTHP is definitely further along in the process. I may pick up a few tomorrow.
Any idea when they expect to hear back from the FDA? Sounds like they sent their response late 2013. I do like the company, but with $100M in debt and cash running out Q2 2014, a lot hinges on speedy FDA approval.